查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863371

基因编辑技术市场按技术平台、应用、最终用户、给药方法和疾病划分－2025-2032年全球预测

Gene Editing Technologies Market by Technology Platform, Application, End User, Delivery Method, Disease Indication - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，基因编辑技术市场将成长至 152.8 亿美元，复合年增长率为 13.04%。

主要市场统计数据
基准年 2024 57.3亿美元
预计年份：2025年 64.8亿美元
预测年份：2032年 152.8亿美元
复合年增长率 (%) 13.04%

本文简要概述了现代基因编辑技术，重点介绍了技术进步、应用研究进展以及各领域相关人员的战略考虑。

过去十年，基因编辑技术已从一项前景看好的实验室技术发展成为重塑生物医学研究、农业科学和工业生物技术的基础工具。核酸酶设计、递送系统和编辑精度的进步使研究人员能够以前所未有的分辨率分析生物系统，而临床项目和转化流程也稳步推进，从概念验证走向治疗应用。因此，各领域的相关人员都在调整其投资组合、投资重点和合作模式，以充分挖掘这些平台的科学和商业性潜力。

近期在基因编辑化学、递送方法和监管措施方面的技术突破如何重塑创新路径和商业性合作

基因编辑技术正经历着一场变革性的转变，这主要得益于精准化学技术的进步、模组化平台架构的建构以及连接发现与应用的成熟生态系统。近期的技术里程碑凸显了碱基编辑和先导编辑方法的重要性，这些方法减少了对双链机制的依赖，提高了特异性并拓宽了治疗范围。同时，TALEN、ZFN 和Meganucleases传统平台技术的持续改进，在那些对客製化标靶和智慧财产权要求较高的领域，仍能提供独特的优势。

评估不断变化的关税政策将如何重塑参与基因编辑研究和生产的组织的供应链、筹资策略和跨境业务营运选择。

贸易和关税政策的变化会对研究投入、供应链以及基因编辑创新成果转化为实用化解决方案的经济效益产生连锁反应。影响试剂、定序耗材、病毒载体组成或专用设备的关税会在筹资策略中造成摩擦点，迫使各机构重新评估采购管道、管理库存并实现供应商多元化。因此，实验室和製造商可能会修改供应商合约和物流安排，以维持营运的连续性和研究效率。

透过细分市场分析，将平台功能、交付选项、应用领域和最终用户需求连结起来，从而指导策略优先排序和产品定位。

细分市场层面的差异化是理解技术能力与应用需求和最终使用者需求交会点的核心。在平台层面，CRISPR、巨型核酸酶、TALEN 和 ZFN 之间的差异对于标靶选择、智慧财产权策略和生产流程至关重要。在 CRISPR 内部，碱基编辑、Cas9 和先导编辑等​​子平台各有优劣。碱基编辑减少了对双链的依赖，并细分为腺嘌呤碱基编辑和胞嘧啶碱基编辑模式，分别针对不同的突变场景。同时，先导编辑扩展了无需供体模板即可实现的精确编辑范围。

区域比较趋势突显了美洲、欧洲、中东、非洲和亚太地区在转化能力、监管方法和商业机会方面的差异。

区域趋势持续对基因编辑研究、开发和应用的轨迹产生重大影响。在美洲，转化研究、创业投资和临床基础设施的优势相结合，为加速治疗计画和扩大生产能力创造了有利条件。该地区的生态系统还拥有密集的合约研究组织和专业服务公司网络，能够支持从药物发现到临床检验的快速迭代。

独特的平台、合作结构和製造能力，定义了基因编辑生态系统中的竞争优势和伙伴关係策略。

基因编辑领域的竞争格局是由专有平台、合作联盟和垂直整合策略共同塑造的。拥有差异化编辑方法或递送平台的机构通常会利用授权合约、共同开发伙伴关係和策略采购来扩大其业务范围，同时保持其核心技术优势。同时，服务供应商和受託研究机构透过提供临床前测试、载体生产和监管支援方面的专业知识，在降低研发风险方面发挥关键作用。

领导者可以采取哪些具体的策略和营运步骤，来协调平台选择、交付优化、供应链韧性和相关人员参与，从而建立可持续的优势。

领导者应采取务实的投资组合策略，平衡平台开发、特定应用投资和营运韧性。首先，应优先考虑与组织优势相符的技术路线。拥有深厚机制专业知识的组织可以投资改进起始基因和基础基因编辑，而拥有成熟病毒载体技术的组织则可以专注于优化嗜性并提高生产效率。同时，应透过有针对性的伙伴关係以及在研发计画早期整合转换终点，加强递送技术和安全性评估能力。

我们采用透明的混合调查方法研究设计，结合专家访谈、文献综合和情境检验，来检验我们对平台、应用程式和营运的推论。

这些研究成果的依据是系统性文献综述、专家访谈以及对技术和应用领域发展轨迹的结构化分析。研究重点包括与转化科学家、临床开发负责人、生产专家和商业负责人进行对话，以获取有关技术限制、监管参与和营运重点的第一手资讯。辅助资料包括同行评审论文、监管指导文件和技术白皮书，以帮助评估平台功能和交付方式。

将科学、营运和政策方面的必要性整合起来，组织必须协调一致，才能将基因编辑技术的进步转化为切实可行的治疗、农业和工业成果。

基因编辑技术正处于一个关键的转折点，技术进步、递送方式创新以及不断变化的监管和政策环境在此交汇融合，既创造了新的机会，也带来了切实的营运挑战。精准编辑化学的进步和多样化的递送方式拓展了基因编辑技术的应用范围，从治疗项目到农业和工业用途，无所不包。同时，地缘政治因素、供应链脆弱性以及公众对安全性和透明度的日益增长的期望，都要求各组织采取整合策略，将卓越的科学技术与前瞻性的运营能力相结合。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将机器学习演算法和 CRISPR 系统结合以提高标靶特异性的进展
  • 加速基因治疗中用于单碱基校正的碱基编辑平台的商业化
  • 扩展基于 CRISPR 的诊断技术，以实现感染疾病的快速现场诊断
  • 开发用于控制蚊子族群的基因驱动技术，以对抗撒哈拉以南非洲的疟疾传播
  • 表观基因编辑工具能够对疾病相关基因表现进行可逆调控。
  • 人类生殖细胞编辑法规结构的演化对研究资金筹措和公众接受度的影响
  • 生技Start-Ups与製药公司合作，推动CAR-T基因编辑治疗方法的研发
  • 利用高保真度的enCas12a突变体最大限度地减少农业基因组编辑中的脱靶突变

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按技术平台分類的基因编辑技术市场

  • CRISPR
    • 基础编辑
      • 腺嘌呤碱基编辑
      • 胞嘧啶碱基编辑
    • Cas9
    • Prime Edit
  • Meganucleases
  • TALEN
  • ZFN

第九章 按应用分類的基因编辑技术市场

  • 农业
    • 农作物
    • 家畜
  • 工业的
    • 生质燃料
    • 生质塑胶
  • 研究工具
    • 侦测
    • 细胞株工程
    • 图书馆筛检
  • 治疗用途
    • Ex Vivo
      • 免疫疗法
      • 干细胞疗法
    • In Vivo
      • 生殖系基因编辑
      • 体细胞基因编辑

第十章 基因编辑技术市场（依最终用户划分）

  • 生物製药公司
    • 大型生物製药公司
    • 中小型生物製药公司
  • 受託研究机构
    • 临床
    • 临床前
  • 医疗中心和医院
    • 诊所
    • 医院
  • 研究机构和学术中心
    • 学术研究
    • 政府实验室

第十一章 基因编辑技术市场（依给药方式划分）

  • 非病毒性
    • 电穿孔
    • 脂质奈米颗粒
    • 显微注射
  • 病毒性的
    • 腺结合病毒
    • 慢病毒
    • 逆转录病毒

第十二章 依疾病分類的基因编辑技术市场

  • 感染疾病
  • 肿瘤学
    • 骨髓恶性肿瘤
    • 固态肿瘤
  • 罕见遗传疾病
    • 囊肿纤维化
    • 镰状细胞性贫血症

第十三章 基因编辑技术市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 基因编辑技术市场（依群体划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国基因编辑技术市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Merck KGaA
    • Roche Holding AG
    • Agilent Technologies, Inc.
    • Sartorius AG
    • Bio-Rad Laboratories, Inc.
    • QIAGEN NV
    • Lonza Group AG
    • Takara Bio Inc.
Product Code: MRR-2E76C3E47FBE

The Gene Editing Technologies Market is projected to grow by USD 15.28 billion at a CAGR of 13.04% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.73 billion
Estimated Year [2025] USD 6.48 billion
Forecast Year [2032] USD 15.28 billion
CAGR (%) 13.04%

A succinct orientation to contemporary gene editing that outlines technological advances, translational momentum, and strategic considerations for stakeholders across sectors

The past decade has seen gene editing evolve from a promising laboratory technique into a foundational tool reshaping biomedical research, agricultural science, and industrial biotechnology. Advances in nuclease design, delivery systems, and editing precision have enabled researchers to interrogate biological systems with unprecedented resolution, while clinical programs and translational pipelines have moved increasingly from conceptual demonstration toward therapeutic application. As a result, stakeholders across disciplines are recalibrating portfolios, investment priorities, and collaborative models to capture the scientific and commercial potential of these platforms.

This introduction synthesizes the current landscape by focusing on the converging technical advances and ecosystem dynamics that matter to executives and R&D leaders. It highlights the interplay between platform innovation and downstream application, the growing importance of delivery and safety considerations, and the shifting expectations around regulatory dialogues and public acceptance. By foregrounding these themes, the narrative sets a pragmatic foundation for subsequent sections that address structural shifts, policy impacts, segmentation intelligence, regional patterns, and actionable recommendations for organizations seeking to navigate the gene editing frontier.

How recent technical breakthroughs in editing chemistry, delivery modalities, and regulatory engagement are recalibrating innovation pathways and commercial collaborations

Gene editing is undergoing transformative shifts driven by refinements in precision chemistry, modular platform architectures, and a maturing ecosystem that links discovery to application. Recent technical milestones have emphasized base editing and prime editing modalities that reduce reliance on double-strand break mechanisms, thereby improving specificity and broadening the set of treatable targets. At the same time, incremental improvements in traditional platforms such as TALEN, ZFN, and meganuclease technologies continue to offer niche advantages where bespoke targeting or intellectual property considerations prevail.

Concurrently, the landscape is changing as delivery innovations-ranging from lipid nanoparticle formulations to viral vector engineering-reshape how therapies reach target tissues and how agricultural or industrial edits are deployed. This nexus of platform sophistication and delivery robustness is catalyzing new partnerships between biotechnology developers, contract research providers, and advanced manufacturing specialists. Moreover, ethical and regulatory discourse has intensified, prompting more proactive engagement between developers and regulators to define acceptable risk thresholds and clinical endpoints. Together, these shifts are creating an environment where iterative technical improvement and pragmatic governance combine to accelerate translational pathways and broaden the practical reach of gene editing applications.

Assessing how evolving tariff policies reshape supply chains, procurement strategies, and cross-border operational choices for entities engaged in gene editing research and production

Policy changes in trade and tariff regimes can have cascading effects on research inputs, supply chains, and the economics of translating gene editing innovations into deployable solutions. Tariffs that affect reagents, sequencing consumables, viral vector components, or specialized equipment create friction points in procurement strategies, forcing organizations to reassess sourcing, inventory, and vendor diversification. In turn, laboratories and manufacturers may alter supplier contracts and logistics arrangements to preserve continuity of operations and maintain research throughput.

Beyond procurement, tariffs can influence strategic decisions such as location of preclinical manufacturing, choices about in-house versus outsourced capabilities, and the structuring of cross-border collaborations. Academic centers, contract research organizations, and biopharmaceutical developers may respond by consolidating key operations in tariff-favored jurisdictions or by deepening partnerships with regional suppliers. Importantly, these adjustments often lead to increased emphasis on supply chain visibility and risk management, with teams investing in scenario planning and buffer strategies. In aggregate, tariff dynamics reshape the operational calculus for organizations engaging in gene editing R&D and production, underscoring the need for adaptable sourcing frameworks and proactive commercial planning.

Segment-focused analysis linking platform characteristics, delivery choices, application domains, and end-user needs to inform strategic prioritization and product positioning

Segment-level differentiation is central to understanding where technical capabilities intersect with application demand and end-user needs. On the platform side, distinctions among CRISPR, meganuclease, TALEN, and ZFN are consequential for target selection, intellectual property strategy, and manufacturing workflows. Within CRISPR, sub-platforms such as Base Editing, Cas9, and Prime Editing offer distinct trade-offs: Base Editing reduces double-strand break reliance and is subdivided into Adenine Base Editing and Cytosine Base Editing modalities that address different mutational contexts, while Prime Editing expands the range of precise edits that can be achieved without donor templates.

Application segmentation further clarifies use cases, spanning Agricultural pursuits with crops and livestock applications, Industrial uses focused on biofuels and bioplastics, Research Tools encompassing assays, cell line engineering, and library screening, and Therapeutic development that separates Ex Vivo approaches-such as immunotherapy and stem cell therapy-from In Vivo strategies, which include germline and somatic editing. End users vary accordingly; large and small biopharmaceutical companies, clinical and preclinical contract research organizations, clinics and hospitals within medical centers, and academic research groups and government laboratories each demand different data packages, regulatory support, and commercialization roadmaps. Delivery method choices between Nonviral techniques like electroporation, lipid nanoparticle formulations, and microinjection, and Viral vectors such as adeno-associated virus, lentivirus, and retrovirus, influence development timelines, scalability, and safety profiles. Disease indication prioritization, including infectious diseases, oncology with its hematological and solid tumor subcategories, and rare genetic disorders such as cystic fibrosis and sickle cell disease, shapes clinical endpoints and patient recruitment strategies. Together, these segmentation vectors provide a multidimensional framework for aligning technology selection, development pathways, and commercial tactics with specific organizational goals.

Comparative regional dynamics that highlight differentiated translational capacity, regulatory approaches, and operational opportunities across the Americas, EMEA, and Asia-Pacific

Regional dynamics continue to exert a strong influence on the trajectory of gene editing research, development, and deployment. In the Americas, strengths in translational research, venture capital formation, and clinical infrastructure create favorable conditions for accelerating therapeutic programs and scaling manufacturing capabilities. This regional ecosystem also hosts a dense network of contract research providers and specialized service firms that support rapid iteration from discovery to clinical validation.

The Europe, Middle East & Africa region presents a heterogeneous landscape in which robust academic ecosystems and well-developed regulatory frameworks coexist with jurisdictions that are still building advanced manufacturing and clinical trial capacity. Policy variability across countries requires careful navigation, yet the region's emphasis on ethical oversight and patient safety frequently leads to close regulatory engagement and high standards for clinical evidence. In the Asia-Pacific region, expanding biotechnology talent pools, growing manufacturing capacity, and proactive industrial strategies have led to intensified activity across both therapeutic and agricultural applications. Cross-border partnerships, regional supply chains, and investments in next-generation facilities characterize this area, creating options for organizations seeking operational redundancy and cost-effective production. These regional patterns underscore the necessity of tailoring commercialization strategies, regulatory approaches, and partner selection to the specific strengths and constraints of each geography.

How proprietary platforms, alliance structures, and manufacturing capabilities define competitive advantage and partnership strategies across the gene editing ecosystem

Competitive dynamics in the gene editing landscape are shaped by a combination of proprietary platforms, collaborative alliances, and vertical integration strategies. Organizations that control differentiated editing modalities or delivery platforms frequently leverage licensing arrangements, co-development partnerships, and strategic sourcing to extend their reach while retaining core technological advantages. Concurrently, service providers and contract research organizations play a pivotal role in de-risking development pathways by offering specialized capabilities in preclinical testing, vector manufacturing, and regulatory support.

Intellectual property management, manufacturing scale-up, and clinical trial design are recurring battlegrounds where firms seek durable advantages. Companies with integrated manufacturing capabilities can accelerate timelines and exert greater control over quality, whereas those focused on platform refinement may rely on partnerships to commercialize downstream applications. Additionally, cross-sector collaborations that combine academic discovery with commercial development continue to be a fertile source of innovation, particularly when they address translational bottlenecks such as delivery, immunogenicity mitigation, and long-term safety monitoring. For decision-makers, understanding how prospective partners or rivals configure these capabilities is essential when evaluating alliance fit, outsourcing decisions, and in-licensing opportunities.

Practical strategic and operational steps leaders can implement to align platform choices, delivery optimization, supply chain resilience, and stakeholder engagement for durable advantage

Leaders should adopt a pragmatic portfolio approach that balances platform development with application-focused investments and operational resilience. Begin by prioritizing technology routes that align with institutional strengths: organizations with deep mechanistic expertise may invest in prime editing or base editing refinement, while those with established viral vector competencies might focus on optimizing tropism and manufacturing throughput. Simultaneously, strengthen delivery and safety assessment capabilities through targeted partnerships and by integrating translational endpoints early in development planning.

Operationally, diversify supply chains and engage in scenario planning to mitigate tariff-related and geopolitical risks. Contractual arrangements that incorporate dual sourcing, regional manufacturing options, and inventory buffering will reduce exposure to procurement disruptions. On the commercial front, cultivate relationships with clinical networks, payers, and patient advocacy groups to ensure that development programs reflect realistic clinical pathways and adoption considerations. Finally, invest in regulatory engagement and ethical communications to build trust with stakeholders and streamline approvals. By executing on these interconnected actions, institutions can better position themselves to translate technical advances into durable clinical, agricultural, or industrial outcomes.

A transparent mixed-method research design that integrates expert interviews, literature synthesis, and scenario testing to validate platform, application, and operational inferences

The research underpinning these insights combined systematic literature review, expert interviews, and structured analysis of technology and application trajectories. Primary engagements included conversations with translational scientists, clinical development leads, manufacturing experts, and commercial strategists to capture first-hand perspectives on technical constraints, regulatory interactions, and operational priorities. Secondary sources consisted of peer-reviewed publications, regulatory guidance documents, and technical white papers that informed assessments of platform capabilities and delivery approaches.

To ensure rigor, the methodology emphasized triangulation across data types and stakeholders, cross-checking claims about platform performance against empirical evidence from preclinical and early clinical studies, and validating operational inferences through practitioner feedback. Scenario analysis was used to explore the implications of policy shifts and supply chain disruptions, while segmentation logic was constructed to reflect the practical decision nodes that organizations face when selecting platforms, applications, delivery methods, and end-user targets. This mixed-method approach produced a structured evidence base that supports actionable recommendations while maintaining transparency about limits and assumptions.

Synthesis of the scientific, operational, and policy imperatives that organizations must reconcile to translate gene editing advances into tangible therapeutic, agricultural, and industrial outcomes

Gene editing stands at a pivotal juncture where technical progress, delivery innovation, and evolving regulatory and policy environments converge to create new opportunities and real operational challenges. Advances in precision editing chemistries and diversified delivery methods have expanded the range of feasible applications from therapeutic programs to agricultural and industrial uses. At the same time, geopolitical factors, supply chain fragility, and heightened expectations for safety and transparency demand that organizations adopt integrated strategies that combine scientific excellence with operational foresight.

Moving forward, sustained progress will require coordinated investment in delivery science, robust engagement with regulatory and ethical stakeholders, and flexible commercial strategies that reflect regional differences and end-user needs. Organizations that successfully navigate this landscape will be those that marry deep technical capabilities with pragmatic supply chain and partnership choices, and who prioritize the translational steps needed to move from laboratory promise to real-world impact. The conclusion underscores the importance of aligning internal capabilities with external realities to realize the full potential of gene editing technologies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing integration of machine learning algorithms with CRISPR systems to enhance target specificity
  • 5.2. Accelerating commercialization of base editing platforms for single nucleotide correction in genetic therapies
  • 5.3. Expansion of CRISPR-based diagnostics enabling rapid point-of-care detection of infectious diseases
  • 5.4. Development of gene drives for mosquito population control to combat malaria transmission in sub-Saharan Africa
  • 5.5. Emergence of epigenome editing tools for reversible regulation of disease-related gene expression profiles
  • 5.6. Evolving regulatory frameworks for human germline editing influencing research funding and public acceptance
  • 5.7. Collaborations between biotech startups and pharmaceutical companies to advance CAR-T gene editing therapeutics
  • 5.8. Adoption of high-fidelity enCas12a variants to minimize off-target mutations in agricultural genome engineering

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gene Editing Technologies Market, by Technology Platform

  • 8.1. CRISPR
    • 8.1.1. Base Editing
      • 8.1.1.1. Adenine Base Editing
      • 8.1.1.2. Cytosine Base Editing
    • 8.1.2. Cas9
    • 8.1.3. Prime Editing
  • 8.2. Meganuclease
  • 8.3. TALEN
  • 8.4. ZFN

9. Gene Editing Technologies Market, by Application

  • 9.1. Agricultural
    • 9.1.1. Crops
    • 9.1.2. Livestock
  • 9.2. Industrial
    • 9.2.1. Biofuels
    • 9.2.2. Bioplastics
  • 9.3. Research Tools
    • 9.3.1. Assays
    • 9.3.2. Cell Line Engineering
    • 9.3.3. Library Screening
  • 9.4. Therapeutic
    • 9.4.1. Ex Vivo
      • 9.4.1.1. Immunotherapy
      • 9.4.1.2. Stem Cell Therapy
    • 9.4.2. In Vivo
      • 9.4.2.1. Germline Gene Editing
      • 9.4.2.2. Somatic Gene Editing

10. Gene Editing Technologies Market, by End User

  • 10.1. Biopharmaceutical Companies
    • 10.1.1. Large Biopharma
    • 10.1.2. Small And Medium Biopharma
  • 10.2. Contract Research Organizations
    • 10.2.1. Clinical
    • 10.2.2. Preclinical
  • 10.3. Medical Centers And Hospitals
    • 10.3.1. Clinics
    • 10.3.2. Hospitals
  • 10.4. Research Institutes And Academic Centers
    • 10.4.1. Academic Research
    • 10.4.2. Government Laboratories

11. Gene Editing Technologies Market, by Delivery Method

  • 11.1. Nonviral
    • 11.1.1. Electroporation
    • 11.1.2. Lipid Nanoparticle
    • 11.1.3. Microinjection
  • 11.2. Viral
    • 11.2.1. Adeno Associated Virus
    • 11.2.2. Lentivirus
    • 11.2.3. Retrovirus

12. Gene Editing Technologies Market, by Disease Indication

  • 12.1. Infectious Diseases
  • 12.2. Oncology
    • 12.2.1. Hematological Malignancies
    • 12.2.2. Solid Tumors
  • 12.3. Rare Genetic Disorders
    • 12.3.1. Cystic Fibrosis
    • 12.3.2. Sickle Cell Disease

13. Gene Editing Technologies Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Gene Editing Technologies Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Gene Editing Technologies Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Thermo Fisher Scientific Inc.
    • 16.3.2. Danaher Corporation
    • 16.3.3. Merck KGaA
    • 16.3.4. Roche Holding AG
    • 16.3.5. Agilent Technologies, Inc.
    • 16.3.6. Sartorius AG
    • 16.3.7. Bio-Rad Laboratories, Inc.
    • 16.3.8. QIAGEN N.V.
    • 16.3.9. Lonza Group AG
    • 16.3.10. Takara Bio Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GENE EDITING TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. GENE EDITING TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GENE EDITING TECHNOLOGIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENINE BASE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENINE BASE EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENINE BASE EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENINE BASE EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENINE BASE EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENINE BASE EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYTOSINE BASE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYTOSINE BASE EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYTOSINE BASE EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYTOSINE BASE EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYTOSINE BASE EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYTOSINE BASE EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CAS9, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CAS9, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CAS9, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CAS9, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CAS9, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CAS9, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRIME EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRIME EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRIME EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRIME EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRIME EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRIME EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEGANUCLEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEGANUCLEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEGANUCLEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEGANUCLEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEGANUCLEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEGANUCLEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TALEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TALEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TALEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TALEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TALEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TALEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ZFN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ZFN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ZFN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ZFN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ZFN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ZFN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CROPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CROPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CROPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CROPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CROPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CROPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIVESTOCK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIVESTOCK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOFUELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOFUELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOFUELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOFUELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOFUELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOFUELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPLASTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPLASTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPLASTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPLASTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPLASTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPLASTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CELL LINE ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CELL LINE ENGINEERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CELL LINE ENGINEERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CELL LINE ENGINEERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CELL LINE ENGINEERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CELL LINE ENGINEERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIBRARY SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIBRARY SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIBRARY SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIBRARY SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIBRARY SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIBRARY SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GERMLINE GENE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GERMLINE GENE EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GERMLINE GENE EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GERMLINE GENE EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GERMLINE GENE EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GERMLINE GENE EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOMATIC GENE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOMATIC GENE EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOMATIC GENE EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOMATIC GENE EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOMATIC GENE EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOMATIC GENE EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LARGE BIOPHARMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LARGE BIOPHARMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LARGE BIOPHARMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LARGE BIOPHARMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LARGE BIOPHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LARGE BIOPHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SMALL AND MEDIUM BIOPHARMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SMALL AND MEDIUM BIOPHARMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SMALL AND MEDIUM BIOPHARMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SMALL AND MEDIUM BIOPHARMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SMALL AND MEDIUM BIOPHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SMALL AND MEDIUM BIOPHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRECLINICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRECLINICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEDICAL CENTERS AND HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEDICAL CENTERS AND HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEDICAL CENTERS AND HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEDICAL CENTERS AND HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEDICAL CENTERS AND HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEDICAL CENTERS AND HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEDICAL CENTERS AND HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEDICAL CENTERS AND HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES AND ACADEMIC CENTERS, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES AND ACADEMIC CENTERS, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES AND ACADEMIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES AND ACADEMIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES AND ACADEMIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES AND ACADEMIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES AND ACADEMIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES AND ACADEMIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ACADEMIC RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ACADEMIC RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ACADEMIC RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ACADEMIC RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GOVERNMENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GOVERNMENT LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GOVERNMENT LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GOVERNMENT LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GOVERNMENT LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GOVERNMENT LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIPID NANOPARTICLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIPID NANOPARTICLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIPID NANOPARTICLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIPID NANOPARTICLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL GENE EDITING TEC